Potential therapeutic strategy for oral squamous cell carcinoma by ErbB3-binding protein 1 gene transfer.

Journal of Cancer Research and Clinical Oncology
Xu ZhouYoucheng Yu

Abstract

An ErbB3-binding protein 1 (Ebp1), was shown to be a potent tumor suppressor in breast and prostate cancer cells. We hypothesized that the inhibitory properties of the Ebp1 gene could be beneficial if ectopically expressed in oral squamous cell carcinoma (OSCC) cells. One OSCC cell line Tca8113 was stably transfected with the complete Ebp1 cDNA or the vector control pcDNA3.1. The inhibitory effect was evaluated using in vitro proliferation assay, cell cycle distribution and anchorage-independent growth in soft agar as well as in vivo tumorigenicity. Stable gene transfer was verified by Western Blot analysis and reverse transcription RT-PCR. Following transfection of Ebp1, a significant reduction in cell proliferation and anchorage-independent growth in soft agar were observed. Ectopic expression of Ebp1 led to a change in cell cycle profile and most importantly, a strong decrease in tumorigenicity of human OSCC cell line in a xenograft mouse model. Ectopic expression of Ebp1 mediates multiple antitumor activities against OSCC, suggesting a potential of Ebp1-based novel therapy for clinical OSCC treatment.

References

Apr 13, 2000·Proceedings of the National Academy of Sciences of the United States of America·J R GrandisJ D Kim
Mar 17, 2001·Nature Reviews. Molecular Cell Biology·Y Yarden, M X Sliwkowski
Mar 27, 2001·Journal of Cellular Physiology·X XiaA W Hamburger
Mar 18, 2003·Proceedings of the National Academy of Sciences of the United States of America·Paul L LeongJennifer Rubin Grandis
May 14, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ezra E W CohenEverett E Vokes
Sep 24, 2004·International Journal of Cancer. Journal International Du Cancer·Michael M Kim, Joseph A Califano
Jun 17, 2005·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J B Vermorken
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Jun 10, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shailaja Kalyankrishna, Jennifer R Grandis
Oct 7, 2006·The EMBO Journal·Beatrix M HorváthLászló Bögre
Feb 3, 2007·International Journal of Cancer. Journal International Du Cancer·Youcheng YuZhiyuan Zhang
Jul 5, 2007·JAMA : the Journal of the American Medical Association·Michalis V KaramouzisAthanassios Argiris
Mar 28, 2008·Expert Review of Anticancer Therapy·Pol M Specenier, Jan B Vermorken
Apr 12, 2008·Cancer Gene Therapy·G Sithanandam, L M Anderson
Jul 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Priya KoppikarJennifer R Grandis
Sep 12, 2008·The New England Journal of Medicine·Jan B VermorkenRicardo Hitt
Apr 25, 2009·Nature Reviews. Clinical Oncology·Jacques BernierJan B Vermorken
May 29, 2009·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun

❮ Previous
Next ❯

Citations

Jun 18, 2015·International Journal of Oncology·Laura PisapiaGiovanna Del Pozzo
Aug 5, 2018·Journal of Cellular Physiology·Dang Quan NguyenLe Xuan Truong Nguyen
Sep 22, 2020·The Journal of Biological Chemistry·Brendan W StevensonJessica K Holien

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Carcinoma, Squamous Cell

Basal cell carcinoma is a form of malignant skin cancer found on the head and neck regions and has low rates of metastasis. Discover the latest research on basal cell carcinoma here.